note analyst day edit
suzi team attend quest analyst day nyc
today keen eye increment detail last night
guidanc updat thesi updat key take
confer well detail note also
lower forecast pt move
reiter outperform acknowledg must
sharpen pencil potenti durat ar relat
issu reach question
thesi updat still struggl put togeth
full pictur guidanc reset await
eventu updat lh w/ respect understand
challeng isol left ad feel modestli
better headwind appear tempor
like degre conservat bake respect
outlook impli acceler growth
appeal despit mute rate albeit
remain convinc level bias upsid
respect core volum share gain cost
leader also superior technolog autom
low market share perpetu challeng
investor approach highli skeptic bia
thu contend take quit time confid
eventu algorithm rebuilt put togeth
view correct share today sensibl howev
given defens profil equiti macro
standpoint wash valuat reiter
outperform rate although must dig emerg
issu patient respons ar detail
pleas see analyst certif import disclosur page report evercor isi affili seek busi
compani cover research report investor awar firm may conflict interest could affect
object report investor consid report singl factor make invest decis
updat guid reflect potenti chang forward
revenu accrual reflect conservat avoid
larg portion revenu earn chang
due receiv adjust
volum impact meaning
weather addit reserv adjust
mostli driven time initi rate
denial time appeal etc
septemb compani fewer
bank deposit day vs last year one
region lab go system
convers delay bill
novemb stabil bit
time receiv key goe back
methodolog involv mani
assumpt could end
wrong extent
compani built higher
disallow rate post
seen septemb
compani feel comfort
revenu compound-annual-growth-rate
overly-aggress disallow
expand plan access headwind
expect captur
provid plethora opportun grow organ growth
opportun
bn spent acquisit last
year dollar capabl build
lot asset arent expos known
new jv prospect expect add bp
issu thu present growth opportun
consolid revenu growth year
allow compani invest advanc diagnost
high growth area oncolog
quest number mark guinan
compani deliv last year
said revenu growth mid-hsd
receiv payer bill
assumpt made around number factor
assumpt may chang time
rate denial
everi year retrospect look made
alway adjust may
bring revenu base cash
septemb bank deposit
one region lab go
system convers
delay bill
still confid
bill get paid
process look
cash collect vs
what book
cash isnt come
mechan
exercis process
dictat need
risk
gave floor guid
potenti chang forward
exampl acquir mm
assum attrit
anywher near use
broader expect reimburs pressur
bp
plan access goe away
expect improv price
across busi
higher margin achiev vs
hospit econom
cost synergi opportun
includ non-compet purchas
pl deal refer
work well
reimburs pressur expect
moder
tailwind headwind contribut
revenu earn growth
carryov test headwind
bp assum minim traction
pama
expect continu acceler top line growth
lab test
adjac add growth
opportun smaller
busi high growth
rate help core busi
earn grow faster revenu
lab market fundament continu remain
fragment pois consolid
pama driven reimburs pressur
open health plan access reduc variat
grow consumer healthcar
drive sharper focu dispar price
lab spend rive share gain
us lab market bn grow modestli
physician portion bn grow
independ lab segment bn grow
grow slower due price
lh
averag commerci price
payer spend bn unnecessari cost variat
mass gener hospit price hospit
mark-up
invest bn acquisit last year
around build capabl
live
goal product cost basi
mm help reduc wage bill pressur
structur chang come industri
provid opportun consolid gain
acquisit north vs
best access insur live
decad provid multi-year oppti grow
hospit system signific pressur
open work
larg portion revenu chang
earn chang receiv
unsur big
smaller piec volum
meaning portion
weather etc
lt guid size contribut better
come
guidanc youll abl build
driven opportun gain share
quick
share count assumpt flat next
reserv adjust differ
year vs prior year
reserv adjust full
initi rate denial significantli
higher end
impact appeal etc
ep jump point greater
organ growth compound-annual-growth-rate next
 acceler
deal take longer close
focus continu build
access biggest
opportun
test categori get stronger
money spent capabl
lot asset acquir
arent expos known issu
refer jim davi everett cunningham
new access total opportun bn mm
share
across us
expect increment
busi time-frame
increment live
live us resid
ca go uhc
tx go
fl go
ny go
ga go
nj go
strong line sight top account hold
us account order lab
esoter advanc dx provid
outreach acquisit jv
new jv prospect expect add bp
consolid revenu growth year
scientif innov advanc dx carri eglinton
precis medicin futur healthcar
opportun advanc dx
seen age payment parti
patient receiv age start reserv
write
complet sell collect agenc
age receiv question
goe back methodolog
make bunch assumpt
assumpt could wrong
extent
advanc diagnost test see
reimburs rate go forward mix
declin price genet test
weve plan price declin
continu take cost
expect captur oppti
time quick get
chunk sit hospit
mean work design
program use hospit lab use one
lower cost lab network
save opportun
built higher disallow rate
there enough rang
compound-annual-growth-rate comfort
overly-aggress
valuat methodolog base mix discount cash flow analysi rel valuat multipl
downsid risk challeng associ integr small outreach lab deal could depress return invest capit
prove distract recent vertic integr hc servic organ lead increas price pressur given
heighten focu unit cost potenti pama relat price cut bleed commerci price ultim
lead neg margin cycl upsid risk pama repriev lead ep upward revis remov key growth
overhang allow resumpt pe expans open contract favor econom allow lh
reap benefit expens small player pressur small lab lead materi up-tick activ highli
attract price allow notabl b/ deploy
laboratori corp america
articl articl
time dissemin novemb
analyst elizabeth anderson suzi yoon ross muken primarili respons prepar research report attest
follow view opinion render research report reflect person view subject compani
issuer part research analyst compens directli relat specif recommend view
research report
